June 3, 2019

Notification of Transfer of Marketing and Manufacturing Approval and Distribution Rights for the transdermal follicle and luteinizing hormone product "Menoaid® Combipatch"

ASKA Pharmaceutical Co., Ltd. (Headquarters: Minato-ku, Tokyo, Japan; President and Representative Director: Takashi Yamaguchi, hereinafter "ASKA Pharmaceutical") and Hisamitsu Pharmaceutical Co., Ltd. (Headquarters: Tosu City, Saga Prefecture, Japan; President and CEO: Kazuhide Nakatomi, hereinafter "Hisamitsu Pharmaceutical") announces that, as of September 1, 2019,the marketing and manufacturing approval of the transdermal follicle and luteinizing hormone product "Menoaid® Combipatch" (Generic name: estradiol, norethisterone acetate, hereinafter referred to as "the investigational product") will be transferred from ASKA Pharmaceutical to Hisamitsu Pharmaceutical.

From September 1, 2019, Hisamitsu Pharmaceutical will provide and collect information about the proper use of the investigational product as the manufacturer and distributor and will ensure a stable supply of the investigational product.

【The outline of the investigational product】

Product name	Menoaid® Combipatch
Active ingredients and strengths	0.62mg estradiol and 2.70mg norethisterone acetate per one system (9cm^2)
Dosage form	White translucent and round shape transdermal patch
Indications and usage	Vasomotor symptoms(hot flashes and seating) due to menopause and ovarian failure
Dosage and administration	Generally, in adults, one system of Menoaid® Combipatch is applied to the abdomen once every 3 to 4 days (twice weekly).